Medplus Health Q4FY26 profit up 25%, stock jumps 11%

Stock spikes after quarterly results

Medplus Health Services shares rallied sharply after the company reported its March-quarter (Q4FY26) numbers. The stock rose 11.3% on the BSE during the session and touched an intra-day high of ₹1,020.35 per share. At 10:01 AM, the gains moderated, but the stock was still up 8.67% at ₹995.55.

The broader market was comparatively steady. The BSE Sensex was up 0.37% at 75,596.27 at the same time, highlighting that the move in Medplus was stock-specific.

What triggered the move

The buying interest followed the release of Q4FY26 financial results. The company posted year-on-year growth across profit, revenue, and operating earnings, while also reporting a modest improvement in profitability ratios.

With retail-facing businesses, quarterly trends in sales and margins tend to influence investor sentiment because they indicate the pace of store-level performance, scale benefits, and cost control.

Q4FY26: Net profit rises to ₹63.97 crore

In the March quarter (Q4FY26), Medplus Health reported a net profit of ₹63.97 crore. This compared with ₹51.32 crore in the year-ago period, translating into a 24.6% year-on-year rise.

The profit increase was one of the headline drivers behind the stock’s sharp reaction, as investors typically respond to both headline earnings growth and the sustainability of operating metrics that support it.

Q4FY26 revenue climbs 23.5% to ₹1,864.39 crore

Revenue from operations in Q4FY26 came in at ₹1,864.39 crore. In the corresponding quarter a year earlier, revenue was ₹1,509.6 crore, indicating a 23.5% year-on-year increase.

The revenue growth provides context for the earnings rise, suggesting that scale expansion played a role in the quarter’s performance.

Operating performance: EBITDA up, margin improves

Medplus reported EBITDA of ₹107.63 crore for Q4FY26, compared with ₹80.33 crore in the year-ago quarter. The company also reported an EBITDA margin of 5.8% versus 5.3% a year earlier.

Margin changes are closely tracked in retail and pharmacy formats because they can reflect product mix, pricing discipline, and operating leverage. In this quarter, the reported numbers show both higher absolute operating earnings and a small year-on-year margin improvement.

Key numbers snapshot

Share price and index performance during the move

The stock’s surge was visible in early trade, with a high of ₹1,020.35. By 10:01 AM, it was trading at ₹995.55, still up 8.67% on the day. During this period, the Sensex was up 0.37% at 75,596.27.

This contrast matters for investors trying to separate company-specific developments from broader market risk-on or risk-off moves.

Additional context from recent quarters

The broader information set around Medplus includes references to Q3 FY2025-26 performance. One data point indicates net profit of ₹57.81 crore in Q3 FY2025-26, up 25.98% year-on-year, with a 4.16% quarter-on-quarter increase in profits.

Another referenced set of Q3 FY26 metrics includes revenue of ₹1,950 crore and PAT of ₹52 crore. Separately, consolidated December 2025 net sales were cited at ₹1,806.12 crore, up 15.67% year-on-year.

While these figures come from different line items and reporting snapshots, together they show the market’s focus on how Medplus sustains growth and manages profitability.

Company identifiers and sector classification

The stock is tracked under NSE: MEDPLUS and BSE: 543427. It is also tagged as a small-cap name in the retail sector within the provided market snapshot.

Why the quarter mattered for investors

The Q4FY26 results combined a year-on-year rise in revenue with improved operating earnings and a higher EBITDA margin. For investors, this mix is often important because it indicates whether growth is coming with stable or improving cost structures.

The immediate price reaction suggests the market welcomed the combination of 23.5% revenue growth and 24.6% profit growth, alongside margin improvement from 5.3% to 5.8%.

Conclusion

Medplus Health shares rallied after the company reported Q4FY26 results showing net profit of ₹63.97 crore and revenue from operations of ₹1,864.39 crore, with EBITDA margin improving to 5.8%. The stock’s move stood out against a modestly higher Sensex, indicating a results-driven reaction.